Best Life Sciences Platforms and Tools Companies in Shanghai, China
The 70 best Life Sciences Platforms and Tools companies in Shanghai, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Sangon Biotech.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Shanghai
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Sangon Biotech Provider of research services and reagents and kits | $300M | 38 mo ago | Series B | 951 | 2003 | — | — | — |
| 2 | Cathay Biotech Producer of industrial biotechnology polymers and solvents | $213M | 126 mo ago | Series B | 2,324 | 1997 | — | 276 patents Patents concentrated in chemistry & materials | — |
| 3 | Genechem Products and services in molecular biology | $56M | 74 mo ago | Series C | 529 | 2002 | Honghua Qu Founder | — | — |
| 4 | Genepoint Biological Technology Platform for cryostorage and long-term preservation | $48M | 41 mo ago | Series D | — | 2015 | Ding Fubin CEO | — | — |
| 5 | Kangpu Developer of small molecule drugs to treat cancer, auto-immune, and inflammatory disease | $39M | 61 mo ago | Series B | 25 | 2011 | Chuansheng Ge Co-Founder & CEO | — | — |
| 6 | Benyao Technology Robotics and artificial intelligence technology to provide automation solutions 64Funding top 37%Market top 39%AI top 45%Talent bottom 49% All 5 signals ▾Fundingtop 37% Markettop 39% AItop 45% Talentbottom 49% Globalbottom 36% Funding: Raised $29.1M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) Market: 100 employees (top 20% of Life Sciences) rank vs industry peers · Fliar Intelligence Index 64/100 | $29M | 19 mo ago | Series A | 100 | 2021 | Yang Tang Founder & CEO | — | 2 launchs · 1 partnership |
| 7 | Shanghai Zhongke New Life Biological Technology Provider of sequencing and bioinformatics services | $28M | 26 mo ago | Series C | 90 | 2003 | Chen Wei CEO | — | — |
| 8 | Imarx Therapeutics Developing and commercialising therapeutics for vascular disorders such as stroke | $27M | 226 mo ago | Acqui-Hired | — | 1996 | Evan unger ex-CEO | — | — |
| 9 | Wancheng Gene Provider of single-cell multi-omics technology for research and industrial-grade production | $16M | 53 mo ago | Series A | — | 2017 | Wu Ziniu Co-Founder | — | — |
| 10 | Shanghai Maibang Biotechnology Developer of animal cell culture media | $16M | 50 mo ago | Series B | — | 2019 | Max Wang Co-Founder & Co-CEO | — | — |
| 11 | GloriousMed Provider of gene testing services for immunodiagnosis and treatment | $16M | 56 mo ago | Series B | — | 2015 | Jin Ge CEO | — | — |
| 12 | Ouyi Biomedical Technology Provider of multi-omics testing services | $16M | 55 mo ago | Series A | — | 2009 | Dong Dong Co-founder | — | — |
| 13 | ET Healthcare Provider of an electrochemiluminescence analyzer | $16M | 61 mo ago | Series D | 11 11 → 23 (+109%) | 2008 | Hong Tan Co-Founder & CEO | 29 patents Medical bedding and flame‑retardant textile technologies with elastomeric cushioning and microbial dispersion | — |
| 14 | Shanghai Doning Biotechnology Provider of cell culture media | $15M | 54 mo ago | Series C | 704 | 2005 | — | — | — |
| 15 | Shanghai Aqu Biotechnology Provider of life sciences instruments and services | $15M | 41 mo ago | Series A | — | 2012 | Deng Junliang CEO | — | — |
| 16 | Yinjia Biotech Provider of protein reagents, kits, and related products for biopharmaceutical applications | $15M | 41 mo ago | Series A | — | 2020 | Wu Yifei Founder & CEO | — | — |
| 17 | Shanghai OPM Biosciences Antibody culture media and vaccine culture products developer | $14M | 69 mo ago | Series B | 261 | 2013 | — | — | — |
| 18 | Origincell Provider of portfolio of biotech research | $11M | 65 mo ago | Series A | — | 2014 | Jianguo Qu Founder | — | — |
| 19 | Hezhuo Biotechnology Provider of cell biology testing services | $7M | 78 mo ago | Series A | — | 2016 | Yang Shen CEO | — | — |
| 20 | Shanghai Baipu Biotechnology Provider of services of proteomics and metabolomics for research purpose | $1M | 33 mo ago | Series A | — | 2017 | Haigui Founder | — | — |
Top 12 Life Sciences Platforms and Tools companies in Shanghai
#1
Series A · Shanghai, Shanghai · founded 2021 · 100 employees$29.1Mraised▾
Robotics and artificial intelligence technology to provide automation solutions. It also offers modular products for the life sciences industry.
- Oct 2024Series A—
- Apr 2023Series A$29.1M
#2
Series B · Shanghai, Shanghai · founded 2003 · 951 employees$300Mraised▾
Provider of research services and reagents and kits. The company offers services like oligos, genes, and peptides syntheses, DNA and NGS sequencing, protein, antibody, and molecular biology-related services. It also sells PCR, enzyme, and other reagents, ELISA, PCR, and other kits.
- Apr 2023Series B$290M
- Aug 2010Series A$10M
#3
Series C · Shanghai, Shanghai · founded 2003 · 90 employees$28.3Mraised▾
Provider of sequencing and bioinformatics services. The company provides services such as high-throughput sequencing, proteomics, PTM modification, metabolomics, post-translational modification group, metabolite, biomedical structure characterization services, and bioinformatics services.
- Apr 2024Series C—
- Aug 2022Series B—
- Apr 2020Series A$28.3M
#4
Series D · Shanghai, Shanghai · founded 2015$48.3Mraised▾
Genepoint Biological Technology has developed a platform for cryostorage and long-term preservation. Their products including cryogenic cell storage automation system, a flexible robot for biobanking, cryo-freezer (LIN vapor freezer), and hoist for freezer.
- Jan 2023Series D$29.5M
- Jul 2021Series C—
- Jun 2021Series C$18.8M
- Aug 2018Series A—
#5
Series A · Shanghai, Shanghai · founded 2020$14.7Mraised▾
Provider of protein reagents, kits, and related products for biopharmaceutical applications. It offers a range of products including protein raw materials, quality control testing kits, and diagnostic reagents. These products support new drug research and development, vaccine development, cell therapy, and diagnostic applications. The company focuses on developing high-quality protein materials and diagnostic testing products.
- Jan 2023Series A$14.7M
#6
Series A · Shanghai, Shanghai · founded 2012$14.8Mraised▾
Provider of life sciences instruments and services. The product catalog of the company includes mass spectroscopy and automatic sample preparation instruments. The services provided by the company include Antibody de novo sequencing, Biomarker research, and Biological sample analysis.
- Jan 2023Series A—
- Jul 2022Series A—
- May 2019Seed—
#7
Series B · Shanghai, Shanghai · founded 1997 · 2324 employees$213Mraised▾
Cathay Biotech producer of industrial biotechnology polymers and solvents. As of Feb 2016, their product portfolio includes dibasic acids, 5- diamine and Terryl® for Textiles. In addition, the company offers services for custom manufacturing of polymers, as well services for process design for fermentation and other bio-production processes.
- Dec 2015PE$135M
- Dec 2006Series B$52M
- May 2006Series A$26M
#8
Series B · Pudong, Shanghai · founded 2019$15.7Mraised▾
Developer of animal cell culture media. The company helps in the development and production of chemical composition (CDM) medium and dry powder medium (DPM). The company develops media for CHO cell culture platform, Hybridoma and myeloma cell culture platform, Virus vaccine cell culture platform, HEK293 and PERC6 cell culture platform, and Insect cell culture platform.
- Apr 2022Series B$15.7M
- Nov 2020Seed—
#9
Series A · Minhang, Shanghai · founded 2017$1.4Mraised▾
Shangai Baipu provides services of proteomics and metabolomics for research purposes. The products provided are for proteomics, metabolomics, genomics, transcriptomics, and bioinformatics. The application of the services is in the field of precision medicine, research, and biomedicine.
- Aug 2023Series A—
- Jan 2020Seed$1.4M
#10
Series B · Pudong, Shanghai · founded 2011 · 25 employees$38.9Mraised▾
Developer of small molecule drugs to treat cancer, auto-immune, and inflammatory disease. The company's product pipeline includes KPG-818 used to treat Systemic Lupus Erythematosus, Multiple Myeloma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Indolent Lymphoma, Adult T-cell Leukemia-Lymphoma, and Chronic Lymphocytic Leukemia; KPG-121 used to treat CRPC/mCRPC and Myelodysplastic Syndrome, and KPG-81 used to treat Hematological Malignancies. The company has identified a protein called cereblon (CRBN) that is the receptor of the CRBN-CRL4 E3 ligase complex (CRL4CRBN) which can be targeted by a class of immunomodulatory small molecule drugs.
- May 2021Series B$38.9M
#11
Series A · Shanghai, Shanghai · founded 2017$15.7Mraised▾
Provider of single-cell multi-omics technology for research and industrial-grade production. The company offers its proprietary products and services like the bioinformatics platform for microfluidic high throughput single-cell analysis platform which can analyze multiple cells parallelly; low throughput single-cell transcriptome sequencing, single-cell immune sequencing, and ATAC- sequencing.
- Dec 2021Series A$15.7M
- Feb 2021Seed—
- Angel—
#12
Series C · Shanghai, Shanghai · founded 2002 · 529 employees$56.4Mraised▾
Genechem engages in developing products and services for molecular biology. The product portfolio of the company includes Gene import tool, Lentivirus Lenti-KD, Lenti-OE, Lenti-CRISPR, Adenovirus Adv-KD, Adv-OE, Adeno - associated virus AAV-KD, AAV-OE, plasmid Trans-KD, Trans-OE library, CDNA-SET, shRNA-SET, Non-coding-SET, CRISPR-Pool, Gene regulation method Gene down regulation Lenti-KD, Lenti-CRISPR, Adv-KD, AAV-KD, Trans-KD, ShRNA-SET, Non-coding-SET, Gene uptake Lenti-OE, Lenti-CRISPR, Adv-OE, AAV-OE, Trans-OE CDNA-SET, Non-coding-SET and, CRISPR-Pool. Additionally, it offers genomics services and custom animal model development services.
- Apr 2020Series C$56.4M
- Mar 2019Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Shanghai is moving
A read on the academic research around Bioinformatics in Shanghai — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 959 papers.
- Shanghai Jiao Tong University287
- Shanghai University of Traditional Chinese Medicine98
- Fudan University Shanghai Cancer Center61
- Shanghai Ninth People\'s Hospital51
- Shanghai Medical College of Fudan University44
- Transcriptome1→49
- Gene1→43
- CRISPR1→10
- Genome editing1→6
- Virtual screening1→5
- Drug1→8
- Drug discovery1→4
- Genomics1→3
- RNA splicing1→3
- Alternative splicing1→3
- Mechanism (biology)1→15
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.